Iodine-123 IBZM SPECT in patients with extrapyramidal movement disorders: Identification of dopamine responders;La SPECT cerebrale con iodio-123 IBZM nei pazienti con disturbi del sistema extrapiramidale: Valutazione della sensibilità alla terapia con farmaci dopaminergici

Radiologia Medica

Volumn 91, Issue 3, 1996, Pages 207-210

  Hierholzer, Johannes ^b   Castelli, Luisa ^a,c   Cordes, Michael ^a   Schelosky, Ludwing ^b   Poewe, Werner ^b   Felix, Roland ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b HUMBOLDT UNIVERSITY   (Germany)

^c NONE   (Italy)

Author keywords

Apomorphine test; Idiopathic Parkinson's disease; Iodine 123 IBZM SPECT; Parkinson's plus syndrome

Indexed keywords

3 IODO 2 HYDROXY 6 METHOXY N ((1 ETHYL 2 PYRROLIDINYL)METHYL)BENZAMIDE; 3-IODO-2-HYDROXY-6-METHOXY-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)BENZAMIDE; APOMORPHINE; BENZAMIDE DERIVATIVE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; PYRROLIDINE DERIVATIVE; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; BRAIN; COMPARATIVE STUDY; EXTRAPYRAMIDAL SYNDROME; FEMALE; HUMAN; INSTRUMENTATION; MALE; METHODOLOGY; MIDDLE AGED; PARKINSON DISEASE; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICS;

ADULT; AGED; AGED, 80 AND OVER; APOMORPHINE; BASAL GANGLIA DISEASES; BENZAMIDES; BRAIN; CONTRAST MEDIA; DOPAMINE AGONISTS; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PARKINSON DISEASE; PYRROLIDINES; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0030098024     PISSN: 00338362     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Brücke T, Podreka I, Angelberger P e Coll: Dopamin D2-receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab 11: 220-228, 1991
2. Cordes M, Henkes H, Laudahn D e Coll: Initial experience with SPECT examinations using (1231) IBZM as a D2-dopamine receptor antagonist in Parkinson's disease. Eur J Rad 12: 182-186, 1991.
3. Ehringer H: Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Wien Klin Wochenschr 38: 1236-1239, 1969.
4. Fahn S, Elton RL: Members of the UP-DRS development committee: Unified Parkinson Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB e Coll. (eds): Recent Developments in Parkinson's disease, vol. 2, pag. 153-164. Macmillan Health Care Information, Florham Park, NJ, 1987
5. Fearnley JM: Age and Parkinson's disease: substantia nigra regional selectivity Brain 114: 2283-2301, 1991.
6. Frankel JP, Lees AJ, Kempster PA e Coll: Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psych 53: 96-101, 1990.
7. Gibb WRG, Lees AJ: The relevance of the whole body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neuros Psych 51 745-752, 1988
8. Hierholzer J, Cordes M, Schelosky L e Coll: Bestimmung der zerebralen Dopamin-(D2)-Rezeptoren-Dichte mit Hilfe der 123-Jod-IBZM-SPECT bei Patienten mit Morbus Parkinson. Fortschr Röntgenstr 157: 390-389, 1992.
9. Hughes AJ, Lees AJ, Stern GM: Apomorphine test to predict dopaminergic responsiveness in Parkinsonian syndromes. Lancet 336: 32-34, 1990
10. Inoue Y, Wagner HN, Wong DF e Coll: Atlas of dopamine receptor images (PET) of the human brain. JCAT 9. 129-140, 1985
11. Jenner P: Clues to the mechanism underlying dopamine cells death in Parkinson's disease J Neurol Neurosurg Psychiat 52 (Suppl) 22-28, 1989
12. Kung HF, Kasliwal R, Pan S e Coll. Dopamin D2-receptor imaging radiopharmaceuticals: synthesis, radio labeling and in vitro binding of R-(+) and S-2-iodio-2-hydroxy-6-methoxy-N-[(1-ethyl-2pyrrolidinyl)methyl] benzamide (IBZM). J Med Chem 31 1039-1043, 1988.
13. Kung HF, Pam S, Kung MP e Coll: In vitro and in vivo evaluation of 123-I IBZM: a potential CNS D2 dopamine receptor imagine agent. J Nucl Med 30 88-92, 1989.
14. Langston JW Current theories on the cause of Parkinson's, disease. J Neurol Neurosurg Psych 52 (Suppl): 13-17, 1989
15. Poewe WH, Lees AJ, Stern GM. Low dose L-Dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology 36: 1528-1530, 1986.
16. Quinn N: Multiple system atrophy: the nature of the beast. J Neurol Neurosurg Psych 52 (Special Suppl): 78-89, 1989.
17. Schwab RS, Amador LV, Levine JY: Apomorphine in Parkinson's disease. Trans Am Neurol Ass 76. 251-253, 1951.